PT KIMIA FARMA TBK DAN ENTITAS ANAKNYA/ AND ITS SUBSIDIARIES

(1)

PT KIMIA FARMA TBK

DAN ENTITAS ANAKNYA/ AND ITS SUBSIDIARIES

Laporan Keuangan Konsolidasian Interim Tanggal 30 Juni 2021 dan 31 Desember 2020 dan Untuk Periode Enam Bulan yang

Berakhir pada Tanggal 30 Juni 2021 dan 2020/

Consolidated Interim Financial Statements As of June 30, 2021 and

(2)

Laporan Keuangan Konsolidasian Interim Consolidated Interim Financial Statements Untuk Periode Enam Bulan yang For the Six-Month Periods Ended

Berakhir pada 30 Juni 2021 dan 2020 June 30, 2021 and 2020

Laporan Posisi Keuangan Consolidated Interim Statements of

Konsolidasian Interim 1 - 2 Financial Position

Laporan Laba Rugi dan Penghasilan Consolidated Interim Statements of Komprehensif Lain Konsolidasian

Interim 3 Profit or Loss and Other

Comprehensive Income

Laporan Perubahan Ekuitas Consolidated Interim Statements of

Konsolidasian Interim 4-5 Changes in Equity

Laporan Arus Kas Konsolidasian Interim 6 Consolidated Interim Statements of Cash Flows

Catatan Atas Laporan Keuangan Notes to the Consolidated Interim

Konsolidasian Interim 7 Financial Statements

(3)

(4)

(5)

(6)

Pihak Berelasi 6, 37, 40 615.378.797 412.835.690 Related Parties

Pihak Ketiga 6, 40 1.594.189.520 1.113.869.099 Third Parties

Piutang Lain-lain 7, 40 305.735.293 234.249.823 Other Receivables

Persediaan 8 2.489.203.513 2.455.828.900 Inventories

Pajak Dibayar di Muka 17.a 329.101.751 390.316.212 Prepaid Taxes

Uang Muka 9 183.253.811 121.498.657 Advances

Biaya Dibayar di Muka 10 177.449.940 114.511.549 Prepaid Expenses

Jumlah Aset Lancar 6.318.621.073 6.093.103.998 Total Current Assets

Aset Tidak Lancar Non-Current Assets

Investasi Jangka Panjang 11 166.010.181 166.010.181 Long Term Investments

Piutang Lain-lain 7, 40 6.541.473 5.040.286 Other Receivables

Aset Tetap - Bersih 12 9.406.627.695 9.402.411.784 Fixed Assets - Net

Aset Hak Guna 13 408.000.360 398.200.582 Right of Use Assets

Properti Investasi 14 1.013.636.000 1.013.636.000 Investment Properties

Aset Tak Berwujud 15 188.014.797 189.092.477 Intangible Assets

Aset Pajak Tangguhan 17.e 70.018.176 66.152.110 Deferred Tax Assets

Aset Tidak Lancar Lainnya 16 205.761.880 229.169.256 Other Non-Current Assets

Jumlah Aset Tidak Lancar 11.464.610.562 11.469.712.676 Total Non-Current Assets

JUMLAH ASET 17.783.231.635 17.562.816.674 TOTAL ASSETS

(7)

30 Juni/ 31 Desember/

June 30, December 31,

2021 2020

LIABILITAS DAN EKUITAS LIABILITIES AND EQUITY

LIABILITAS LIABILITIES

Liabilitas Jangka Pendek Current Liabilities

Utang Bank Jangka Pendek 18, 37, 40 4.596.872.792 4.379.678.025 Short-Term Bank Loans

Utang Usaha: Accounts Payable:

Pihak Berelasi 19, 37, 40 119.681.873 49.308.534 Related Parties

Pihak Ketiga 19, 40 1.121.449.490 1.238.979.187 Third Parties

Utang Lain-lain Pihak Ketiga 20, 39, 40 132.412.456 118.949.943 Other Payable to Related Parties

Utang Pajak 17.b 59.746.904 46.447.433 Taxes Payable

Beban Akrual 21, 40 139.779.228 165.799.257 Accrued Expenses

Penjualan Diterima di Muka -- -- Unearned Revenue

Utang Jangka Panjang yang Jatuh Current Portion of Long-Term

Tempo dalam Satu Tahun: Liabilities:

Medium Term Notes 22, 37, 40 -- 600.000.000 Medium Term Notes

Utang Bank 23, 37, 40 225.544.136 172.205.123 Bank Loans

Liabilitas Sewa -- 742.428 Lease Liabilities

Utang Pembiayaan Konsumen 24, 40 19.337.801 14.831.967 Consumer Financing Payables

Jumlah Liabilitas Jangka Pendek 6.414.824.680 6.786.941.897 Total Current Liabilities

Liabilitas Jangka Panjang Non-Current Liabilities

Utang Jangka Panjang-Setelah Dikurangi Long-Term Loan-Net of

Bagian Jatuh Tempo dalam Satu Tahun Current Maturities

Medium Term Notes 22, 37, 40 500.000.000 500.000.000 Medium Term Notes

Utang Bank 23, 37, 40 2.627.355.007 2.063.153.399 Bank Loans

Liabilitas Sewa 28.230.737 22.414.876 Lease Liabilities

Utang Pembiayaan Konsumen 24, 40 23.305.314 7.919.039 Consumer Financing Payables

Liabilitas Imbalan Kerja 25 652.028.882 638.584.548 Employment Benefits Liabilities

Liabilitas Pajak Tangguhan 17. e. 417.820.419 438.130.869 Deferred Tax Liabilities

Jumlah Liabilitas Jangka Panjang 4.248.740.359 3.670.202.731 Total Non-Current Liabilities

JUMLAH LIABILITAS 10.663.565.039 10.457.144.628 TOTAL LIABILITIES

EKUITAS EQUITY

Modal Saham - Nilai Nominal Share Capital - Par Value

Rp100 (angka penuh) Rp100 (full amount)

Modal Dasar - 20.000.000.000 saham Authorized Capital - 20,000,000,000 shares

terdiri dari 1 saham Seri A Dwiwarna consist of 1 share of Serie A Dwiwarna

dan 19.999.999.999 saham Seri B and 19,999,999,999 shares of Serie B

Modal Ditempatkan dan Disetor Penuh - Issued and Fully Paid -

5.554.000.000 saham yang terbagi 5,554,000,000 shares consist of

atas 1 saham Seri A Dwiwarna 1 share of Serie A Dwiwarna

dan 5.553.999.999 saham Seri B 26 555.400.000 555.400.000 and 5,553,999,999 shares of Serie B

Tambahan Modal Disetor - Neto 27 (885.401.366) (885.401.366) Additional Paid-In Capital - Net

Modal Proforma yang Timbul Proforma Capital Arising

Karena Transaksi Akuisisi From Accquisition of Entity

Entitas Pengendali -- -- Under Common Control

Penghasilan Komprehensif Lain 28 5.010.983.980 5.032.161.649 Other Comprehensive Income

Saldo Laba: Retained Earnings:

Telah Ditentukan Penggunaannya 2.284.181.022 2.273.597.721 Appropriated

Belum Ditentukan Penggunaannya 57.600.338 17.638.834 Unappropriated

Jumlah Ekuitas yang Dapat Diatribusikan Total Equity Attributable to

kepada Pemilik Entitas Induk 7.022.763.974 6.993.396.838 Owners of The Parent Entity

Kepentingan Nonpengendali 29 96.902.622 112.275.208 Non-controlling Interest

JUMLAH EKUITAS 7.119.666.596 7.105.672.046 TOTAL EQUITY

JUMLAH LIABILITAS DAN EKUITAS 17.783.231.635 17.562.816.674 TOTAL LIABILITIES AND EQUITY

(8)

PENJUALAN NETO 31, 37 5.558.524.127 4.687.803.350 NET SALES

BEBAN POKOK PENJUALAN 32 (3.697.549.807) (2.897.951.468) COST OF GOODS SOLD

LABA BRUTO 1.860.974.320 1.789.851.882 GROSS PROFIT

Beban Usaha 33 (1.553.382.611) (1.514.845.923) Operating Expenses

Pendapatan Lain-lain - Bersih 34 56.644.607 94.441.871 Other Income - Net

Selisih Kurs Mata Uang Asing - neto (6.484.052) (4.414.126) Foreign Exchange Difference - Net

LABA USAHA 357.752.264 365.033.705 OPERATING INCOME

Beban Keuangan 35 (288.404.123) (293.202.106) Finance Cost

Penghasilan Keuangan 35 7.155.523 9.168.917 Finance Income

LABA SEBELUM PAJAK 76.503.664 81.000.516 INCOME BEFORE TAX

MANFAAT (BEBAN) PAJAK PENGHASILAN INCOME TAX BENEFITS (EXPENSES)

Pajak Kini 17.d (39.093.211) (39.585.639) Current Tax

Pajak Tangguhan 17.e 15.987.740 9.586.059 Deferred Tax

Total Pajak Penghasilan (23.105.471) (29.999.580) Total Income Tax

LABA TAHUN BERJALAN 53.398.193 51.000.936 INCOME FOR THE YEAR

PENGHASILAN KOMPREHENSIF LAIN OTHER COMPREHENSIVE INCOME

Pos yang Tidak akan Direklasifikasi Item that Will Not be Reclassified

ke Laba Rugi: -- to Profit or Loss:

Pengukuran Kembali atas Program Remeasurement on Defined

Imbalan Pasti 25 (37.221.723) (23.042.878) Benefits Plan

Selisih Revaluasi Aset Tetap Tanah

dan Properti Investasi 12 -- -- Asset Revaluation Reserve

Selisih Penilaian Investasi Reserve for Changes of Fair Value of

Saham -- (18.416.000) for Sale Financial Assets

Pajak Penghasilan Terkait 17.e 8.188.779 5.760.720 Related Income Tax

Pos yang akan Direklasifikasi Item that May be Reclassified

ke Laba Rugi: Subsequently to Profit or Loss:

Selisih Kurs karena Penjabaran Foreign Currency Translation

Laporan Keuangan 7.157.420 (14.919.595) Adjustments

JUMLAH LABA (RUGI) KOMPREHENSIF TOTAL COMPREHENSIVE INCOME

TAHUN BERJALAN 31.522.669 383.183 (LOSS) FOR THE YEAR

Jumlah Laba Tahun Berjalan Total Income for The Current year

yang Dapat Diatribusikan kepada: Attributable to:

Pemilik Entitas Induk 57.600.339 48.575.101 Owners of the Parent

Kepentingan Nonpengendali 29 (4.202.146) 2.425.835 Non-Controlling Interest

53.398.193 51.000.936

Jumlah Laba Komprehensif Tahun Berjalan Total Comprehensive Income for The

yang Dapat Diatribusikan kepada: Current Year Attributable to:

Pemilik Entitas Induk 36.422.669 (4.446.640) Owners of the Parent

Kepentingan Nonpengendali 29 (4.900.000) 4.829.823 Non-Controlling Interest

31.522.669 383.183

Laba per Saham Dasar Basic Earnings per Share

yang Dapat Diatribusikan kepada Attributable to

Pemilik Entitas IndukPemilik Entitas Induk (angka penuh) 36 9,61 8,75 Owners of the Parent (full amount)

(9)

Modal Proforma Yang Timbul Karena Penyajian Kembali Laporan

Modal Keuangan/

Ditempatkan Tambahan Proforma Capital

dan Disetor Modal Disetor/ Arising From Komponen Telah Belum Kepentingan Jumlah Ekuitas/

Penuh/ Additonal Restatement Ekuitas Ditentukan Ditentukan Nonpengendali/ Total

Catatan/ Issued and Fully Paid-in of Financial Lainnya/ Penggunaannya/ Penggunaannya/ Jumlah/ Non-Controlling Equity

Notes Paid-in Capital Capital Statement Other Equity

Components

Appropriated Unappropriated Total Interest

SALDO PER 31 DESEMBER 2019 555.400.000 (885.401.366) -- 5.114.989.822 2.469.629.476 (12.724.002) 7.241.893.930 171.032.897 7.412.926.827 BALANCE AS OF DECEMBER 31, 2019

Penyesuaian Saldo Awal Sehubungan dengan Beginning Balance Adjustment for

Penerapan PSAK 71, Setelah Pajak 43 -- -- -- -- (183.307.753) -- (183.307.753) (26.269.587) (209.577.340) Implementation of PSAK 71, Net of Tax

SALDO PER 1 JANUARI 2020 555.400.000 (885.401.366) -- 5.114.989.822 2.286.321.723 (12.724.002) 7.058.586.177 144.763.310 7.203.349.487 BALANCE AS OF JANUARY 1, 2020

Laba Tahun Berjalan -- -- -- -- -- 48.575.101 48.575.101 2.425.835 51.000.936 Income For The Year

Penghasilan Komprehensif Lain -- -- -- (4.446.640) -- -- (4.446.640) 4.829.823 383.183 Other Comprehensive Income

Laba Ditahan Ditentukan Penggunaannya 28 -- -- -- -- (12.724.002) 12.724.002 -- -- -- Appropriated Retained Earnings

Pembagian Dividen dari Entitas Anak untuk Dividend Distribution from Subsidiaries

Kepentingan Nonpengendali 30 -- -- -- -- -- -- -- -- -- for Non-Controlling Interest

SALDO PER 30 JUNI 2020 555.400.000 (885.401.366) -- 5.110.543.182 2.273.597.721 48.575.101 7.102.714.637 152.018.968 7.254.733.605 BALANCE AS OF JUNE 30, 2020

SALDO PER 1 JANUARI 2020 555.400.000 (885.401.366) -- 5.114.989.822 2.286.321.723 (12.724.002) 7.058.586.177 144.763.310 7.203.349.487 BALANCE AS OF JANUARY 1, 2020

Laba Tahun Berjalan -- -- -- -- -- 17.638.834 17.638.834 2.786.922 20.425.756 Income For The Year

Penghasilan Komprehensif Lain -- -- -- (82.828.173) -- -- (82.828.173) (2.952.038) (85.780.211) Other Comprehensive Income

Laba Ditahan Ditentukan Penggunaannya 28 -- -- -- -- (12.724.002) 12.724.002 -- -- -- Appropriated Retained Earnings

Kepentingan Nonpengendali 30 -- -- -- -- -- -- -- (32.322.987) (32.322.987) for Non-Controlling Interest

SALDO PER 31 DESEMBER 2020 555.400.000 (885.401.366) -- 5.032.161.649 2.273.597.721 17.638.834 6.993.396.838 112.275.207 7.105.672.045 BALANCE AS OF DECEMBER 31, 2020

Laba Tahun Berjalan -- -- -- -- -- 57.600.339 57.600.339 (4.202.146) 53.398.193 Income For The Year

Penghasilan Komprehensif Lain -- -- -- (21.177.670) -- -- (21.177.670) (697.854) (21.875.524) Other Comprehensive Income

Laba Ditahan Ditentukan Penggunaannya 28 -- -- -- -- 10.583.301 (10.583.301) -- -- -- Appropriated Retained Earnings

Pembagian Dividen 30 -- -- -- -- -- (7.055.534) (7.055.534) -- (7.055.534) Dividend Distribution

Kepentingan Nonpengendali 30 -- -- -- -- -- -- -- (10.472.585) (10.472.585) for Non-Controlling Interest

SALDO PER 30 JUNI 2021 555.400.000 (885.401.366) -- 5.010.983.979 2.284.181.022 57.600.338 7.022.763.973 96.902.622 7.119.666.595 BALANCE AS OF JUNE 30, 2021

Ekuitas Yang Dapat Diatribusikan kepada Pemilik Ekuitas Induk/ Equity Attributable to Owners of the Parent Entity

Saldo Laba/ Retained Earnings (Accumulated Deficit)

(10)

Kas yang Dihasilkan dari Aktivitas Operasi 1.211.654.078 1.712.539.171 Cash Provided from Operating Activities

Penghasilan Bunga 7.155.523 9.168.917 Interest Received

Pembayaran Bunga (288.404.123) (293.202.106) Payment of Interest

Penerimaan Pajak 193.652.651 289.790.497 Receipt of Tax

Pembayaran Pajak Penghasilan (39.093.211) (144.170.059) Payment of Income Tax

Pembayaran Operasi Lain-lain -- 21.435.724 Payment of Other Operating Expenses

Pembayaran Kepada Karyawan (1.006.016.599) (997.176.624) Payment to Employee

Pembayaran Beban Usaha (738.165.958) (816.175.604) Payments for Operating Expenses

Arus Kas Bersih Diperoleh dari (Digunakan untuk) Net Cash Flows Provided by (Used in)

Aktivitas Operasi (659.217.639) (217.790.084) Operating Activities

ARUS KAS DARI CASH FLOWS FROM

AKTIVITAS INVESTASI INVESTING ACTIVITIES

Hasil Pelepasan Aset Tetap 12 451.553 -- Proceeds from Disposal of Fixed Assets

Perolehan Aset Tetap 12 (186.661.003) (285.519.105) Acquisitions of Fixed Assets

Penambahan Aset Takberwujud 14 (628.956) (1.610.998) Addition of Intangible Assets

Penerimaan Dividen 6.710.731 -- Receipt of Dividend Income

Arus Kas Bersih Digunakan untuk Net Cash Flows Used in

Aktivitas Investasi (180.127.675) (287.130.103) Investing Activities

ARUS KAS DARI CASH FLOWS FROM

AKTIVITAS PENDANAAN FINANCING ACTIVITIES

Pencairan Utang Bank Jangka Pendek 7.424.690.002 (798.392.343) Drawdown of Short Term Bank Loans

Pembayaran Utang Bank Jangka Pendek (7.207.495.235) 571.031.946 Payment of Short Term Bank Loans

Pencairan Utang Bank Jangka Panjang 617.540.621 -- Drawdown of Long Term Bank Loans

Pembayaran Medium Term Notes 21 (600.000.000) -- Payment of Medium Term Notes

Penambahan Liabilitas Sewa (17.058.305) Addition of Lease Liability

Pembayaran Pembiayaan Konsumen -- (2.738.801) Payment of Customer Financing Payable

Pembayaran Dividen Tunai (702.224) (3.095.370) Cash Dividend Paid

Kepentingan Nonpengendali (10.472.585) -- for Non-Controlling Interest

di Entitas Anak -- --

in Subsidiaries

Arus Kas Bersih Diperoleh (Digunakan) dari Net Cash Flows Provided by (Used in)

Aktivitas Pendanaan 206.502.274 (233.194.568) Financing Activities

PENURUNAN KAS DECREASE IN CASH

DAN SETARA KAS (632.843.040) (738.114.755) AND CASH EQUIVALENTS

DAMPAK DARI PERUBAHAN KURS EXCHANGE RATES FLUCTUATION EFFECTS

TERHADAP KAS DAN SETARA KAS 7.157.420 (4.858.301) ON CASH AND CASH EQUIVALENTS

KAS DAN SETARA KAS CASH AND CASH EQUIVALENTS

AWAL TAHUN 1.249.994.068 1.360.268.286 AT BEGINNING OF YEAR

KAS DAN SETARA KAS CASH AND CASH EQUIVALENTS

AKHIR PERIODE 624.308.448 617.295.230 AT END OF PERIOD

Tambahan informasi aktivitas yang tidak

mempengaruhi arus kas disajikan pada Catatan 42 Additional information of non-cash activities are presented in note 42

(11)

1. UMUM 1. GENERAL

1. a. Pendirian dan Informasi Umum 1. a. Establishment and General Information PT Kimia Farma Tbk (“Perusahaan”)

didirikan berdasarkan Akta No. 18 tanggal 16 Agustus 1971 dari Soelaeman Ardjasasmita, S.H., Notaris di Jakarta, yang diubah dengan Akta No. 18 tanggal 11 Oktober 1971 dari Notaris yang sama.

Akta pendirian beserta perubahannya telah disahkan oleh Menteri Kehakiman Republik Indonesia daIam Surat Keputusan No. JA5/184/21 tanggal 14 Oktober 1971, yang didaftarkan pada buku registrasi No 2888 dan No. 2889 tanggal 20 Oktober 1971 di Kantor Pengadilan Negeri Jakarta dan telah diumumkan dalam Berita Negara Republik Indonesia No. 90, Tambahan No. 508 tanggal 9 November 1971.

Anggaran Dasar Perusahaan telah mengalami beberapa kali perubahan, terakhir dengan Akta Notaris No.15 tanggal 31 Januari 2020 dari Mochamad Nova Faisal, S.H., M.Kn., sehubungan dengan perubahan Anggaran Dasar Perusahaan. Atas perubahan ini, telah tercatat di Kementerian Hukum dan Hak Asasi Manusia Republik Indonesia berdasarkan Surat Keputusan No. AHU- 0041281.AH.01.11.Tahun 2020 tanggal 28 Februari 2020.

PT Kimia Farma Tbk (“the Company”) was

established on the Deed

No. 18 dated August 16, 1971 of Soelaeman Ardjasasmita S.H., Notary in Jakarta, which subsequently was changed with Deed No. 18 dated October 11, 1971 from the same Notary. The deed of establishment and its amendment have been approved by the Minister of Justice of Republic of Indonesia in his decree No.

JA5/184/21 dated October 14, 1971, and was registered at the registration book at the Jakarta Court No 2888 and No 2889 dated October 20, 1971 and published in the State Gazette No. 90 additional No.

508 dated November 9, 1971. The Company’s Articles of Association have been amended several times, most recently by the Deed No. 15 dated January 31, 2020 of Mochamad Nova Faisal, S.H., M.Kn., concerning the changes in Company’s Articles of Association. The amended deed had been reported to the Ministry of Law and Human Rights of the Republic of Indonesia with Acceptance Notice No. AHU-0041281.AH.01.11.Tahun 2020 dated February 28, 2020.

(12)

Perusahaan mulai beroperasi secara komersial sejak tahun 1817 yang pada saat itu bergerak dalam bidang distribusi obat dan bahan baku obat. Pada tahun 1958, pada saat Pemerintah Indonesia menasionalisasikan semua Perusahaan Belanda, status Perusahaan diubah menjadi beberapa Perusahaan Negara.

Pada tahun 1969, beberapa Perusahaan Negara tersebut diubah menjadi satu Perusahaan yaitu Perusahaan Negara Farmasi dan Alat Kesehatan Bhinneka Kimia Farma disingkat PN Farmasi Kimia Farma. Pada tahun 1971, berdasarkan Peraturan Pemerintah No 16 Tahun 1971 status Perusahaan Negara tersebut diubah menjadi Persero dengan nama PT Kimia Farma Pada tanggal 4 Juli 2001, PT Kimia Farma (Persero) kembali mengubah statusnya menjadi perusahaan publik dengan nama PT Kimia Farma (Persero) Tbk.

The Company started its commercial operations in 1817, at that time the Company was engaged in the distribution of medicines and raw pharmaceutical materials. In 1958, the Government of the Republic of Indonesia nationalized all Dutch Companies and converted those companies into state-owned companies. In 1969, state owned companies merged into one Company named Perusahaan Negara Farmasi and Alat Kesehatan Bhinneka Kimia Farma or simply PN Farmasi Kimia Farma. In 1971, based on Government Regulation No 16 year 1971, the Company’s status was changed into a state owned enterprise under the name PT Kimia Farma (Persero). On July 4, 2001, PT Kimia Farma (Persero) change its status to public company under the name PT Kimia Farma (Persero) Tbk.

Berdasarkan Akta Risalah Umum Pemegang Saham Luar Biasa No. 18 tanggal 18 September 2019, disetujui perubahan Anggaran Dasar Perseroan pasal 1 tentang Nama dan Tempat Kedudukan Perseroan, semula PT Kimia Farma (Persero) Tbk diubah menjadi PT Kimia Farma Tbk terkait dengan pembentukan Holding BUMN Farmasi.

Akta tersebut disetujui melalui Surat Keputusan No. AHU-AH.01.03-0115053 Tahun 2020 pada tanggal 28 Februari 2020.

According to Akta Risalah Umum Pemegang Saham Luar Biasa No. 18 dated September 18, 2019, it was agreed to change its Company’s Articles of Association article 1 about Name and Domicile of the Company, formerly PT Kimia Farma (Persero) Tbk and changed into PT Kimia Farma Tbk due to the formation State-owned Enterprise Pharmaceutical Holding. The deed was approved by the Ministry of Law and Human Rights with Decree No. AHU- AH.01.03-0115053 Tahun 2020 on February 28, 2020.

(13)

1. UMUM (Lanjutan) 1. GENERAL (Continued) 1. a. Pendirian dan Informasi Umum

(Lanjutan)

1. a. Establishment and General Information (Continued)

Perusahaan berkedudukan di Jakarta dengan pabrik berlokasi di Jakarta, Bandung, Semarang, Watudakon (Mojokerto) dan Denpasar. Perusahaan juga memiliki satu unit distribusi yang

berlokasi di Jakarta.

Kantor Pusat Perusahaan beralamat di Jalan Veteran Nomor 9 Jakarta.

The Company is domiciled at Jakarta with its factories located at Jakarta, Bandung, Semarang, Watudakon (Mojokerto) and Denpasar. The Company also has one distribution unit located in Jakarta. The Company’s head office in Veteran Street's No. 9, Jakarta.

Sesuai dengan pasal 3 Anggaran Dasar Perusahaan, ruang lingkup kegiatan Perusahaan terutama meliputi bidang industri, pertambangan, perdagangan besar dan eceran, aktivitas kesehatan manusia, penyediaan akomodasi, pendidikan, aktivitas professional, ilmiah dan teknis, aktivitas keuangan dan asuransi, pertanian, informasi dan komunikasi dan aktivitas jasa lainnya.

In accordance with Article 3 of the Company's Articles of Association, the Company’s scope of activities is industry, mining, wholesale and retail trade, human health activities, accommodation, education, professional acitivities, scientific and technical, finance and insurance activities, information and communication and other service activities.

Hasil produksi Perusahaan dipasarkan di dalam dan di luar negeri, yaitu ke Asia, Eropa, Australia, Afrika dan Amerika.

The Company’s products are distributed locally and for export, such in Asia, Europe, Australia, Africa and America.

PT Bio Farma (Persero) adalah pemegang saham mayoritas Perusahaan, dengan pemilikan 90,03%.

PT Bio Farma (Persero) is the Company’s majority shareholder with 90.03%

ownership.

(14)

Susunan pengurus Perusahaan berdasarkan Risalah Rapat Umum Pemegang Saham No. 19 tanggal 28 April 2021 dan Akta Pernyataan Keputusan Rapat No. 24 tanggal 29 Juli 2020 dari M. Nova Faisal S.H., M.Kn.

adalah sebagai berikut:

The composition of the Company’s management according to General Shareholder Meeting Statement No. 19 dated April 28, 2021 and Meeting Decision Statement Deed No. 24 dated July 29, 2020 from M. Nova Faisal, S.H., M.Kn. are as follows:

Komisaris Utama Prof. Dr. Abdul Kadir, Ph.D., dr. Alexander K. Ginting S.,Sp.P(K)., President Commissioner

Sp.THT-KL (K)., MARS. FCCP.

Komisaris Dr. Subandi Sardjoko, M.Sc. Dr. Subandi, M.Sc. Commissioner

Dwi Ary Purnomo, S.E., M.H. Chrisma Aryani Albandjar , S.Sos., M.M., M.A.

Komisaris Independent

Independen dr. Musthofa Fauzi, Sp.An. dr. Musthofa Fauzi, Sp.An. Commissioner

dr. Kamelia Faisal, MARS. --

Direktur Utama Drs. Verdi Budidarmo,Apt Drs. Verdi Budidarmo,Apt President Director

Direktur Umum dan General affair and

Human Capital Dharma Syahputra, S.T., M.M. Dharma Syahputra, S.T., M.M. Human Capital Director

Direktur Produksi dan Production and

Supply Chain Drs. Andi Prazos, M.M. Drs. Andi Prazos, M.M. Supply Chain Director

Direktur Keuangan Ir. Lina Sari. M.M. Pardiman, S.E., M.M Finance Director

Direktur Pengembangan Business Development

Bisnis Drs. Imam Fathorrahman, M.M Drs. Imam Fathorrahman, M.M Director

2021 2020

Pada tanggal 30 Juni 2021 dan 31 Desember 2020 jumlah karyawan tetap adalah masing-masing 12.018 dan 11.891 orang (tidak diaudit).

As of June 30, 2021 and December 31, 2020 total permanent employees are 12,018 and 11,891, respectively (unaudited).

(15)

1. UMUM (Lanjutan) 1. GENERAL (Continued) 1. c. Komite Audit, Sekretaris Perusahaan

dan Kepala Internal Audit Perusahaan 1. c. Audit Committee, Corporate Secretary and Internal Audit

Susunan kepengurusan Komite Audit Perusahaan dan Komite GCG dan Pemantau Risiko berdasarkan Keputusan Dewan Komisaris PT Kimia Farma Tbk No.KEP-003/KOM-KF/V/2021 tanggal 4 Mei 2021 dan No. KEP-011/KOM- KF/XII/2020 tanggal 17 Desember 2020

pada tanggal

30 Juni 2021 dan 31 Desember 2020 adalah sebagai berikut:

The composition of the Company’s Audit Committee and GCG and Risk Monitor according to Decision of the Board Commissioners PT Kimia Farma Tbk No.KEP-003/KOM-KF/V/2021 dated

May 4, 2021 and

No.KEP-011/KOM-KF/XII/2020 dated December 17, 2020 as of June 30, 2021 and December 31, 2020 are as follows:

Ketua Komite Audit dr. Musthofa Fauzi, Sp.An. Ir. Nurrachman Chief of Audit Committee

Anggota Komite Audit Dr. Subandi, M.Sc. Dr. Subandi, M.Sc. Audit Committee Members

Tjahjo Winarto, Ak., Tjahjo Winarto, Ak., M.B.A.,PIA., CA., CRMO. M.B.A.,PIA., CA., CRMO.

Sri Yanto Ak., CA., ASA Sri Yanto Ak., CA., ASA

Ketua Komite GCG & PMR Dwi Ary Purnomo, S.E., M.H. Prof. Dr. Wahono Sumaryono, Chief of GCG & PMR Committee Apt,APU.

Anggota Komite GCG Bintang Sarwo Budhi, Ak. Chrisma Aryani Albandjar , GCG Committee Members Drs. Usep Hendarwien, M.M., S.Sos., M.M., M.A.

Apt. Bintang Sarwo Budhi, Ak.

Drs. Usep Hendarwien, M.M., Apt

Sekretaris Perusahaan Ganti Winarno Putro, S.Si., Apt. Ganti Winarno Putro, S.Si., Apt. Corporate Secretary Kepala Internal Audit Budi Her Utomo S.H.,M.Kn., Budi Her Utomo S.H.,M.Kn., Head of Internal Audit

M.M.,CLA.,QIA.,CPIA. M.M.,CLA.,QIA.,CPIA.

2020 2021

Sekretaris Perusahaan adalah Ganti Winarno Putro S.Si., yang diangkat berdasarkan surat No.KEP.114A/DIR/XI/2017 tanggal 1 November 2017.

The Corporate Secretary is Ganti Winarno Putro S.Si., who was appointed based on letter No.KEP.114A/DIR/XI/2017 dated November 1, 2017.

Kepala Internal Audit Perusahaan pada 30 Juni 2021 dijabat oleh Budi Her Utomo S.H.,M.Kn.,M.M.,CLA.,QIA.,CPIA yang diangkat berdasarkan surat No.

KEP/046/DIRUM/HC-KP/X/ 2020 tanggal 9 November 2020.

Head of Internal Audit as of

June 30, 2021

is Budi Her Utomo

S.H.,M.Kn.,M.M.,CLA.,QIA.,CPIA who was appointed based on letter No.

KEP/046/DIRUM/HC-KP/X/ 2020 dated November 9, 2020.

(16)

entitas anak yang dikonsolidasi sebagai berikut:

consolidated subsidiaries as follows:

Entitas Anak / Domisili / Kegiatan Usaha / Mulai Beroperasi /

Subsidiaries Domicile Core Business Start Operation 2021 2020 2021 2020

Pemilikan Langsung/

Direct Ownership

PT Kimia Farma Apotek (KFA) Jakarta Apotek (Ritel)/ Pharmacy 4 Januari 2003 / 99,99% 99,99% 3.573.249.260 3.414.642.987 January 4, 2003

PT Kimia Farma Trading Jakarta Distribusi Obat- 4 Januari 2003 / 99,99% 99,99% 2.874.924.443 2.622.042.610

& Distribution (KFTD) obatan/ Medicine Distribution January 4, 2003

PT Sinkona Indonesia Subang Pabrik Kina/ Quinine Factory 25 Oktober 1986 / 51,00% 51,00% 301.012.693 286.538.234

Lestari (SIL) October 25, 1986

PT Kimia Farma Sungwun Cikarang Pabrik Bahan Baku Obat/ 25 Januari 2016 / 80,67% 80,67% 181.091.749 138.304.205

Pharmacopia (KFSP) Drug Materials Plant January 25, 2016

Kimia Farma Dawaa, Arab Apotek (Ritel) dan Distribusi 5 Maret 2018 / 60,00% 60,00% 126.222.841 193.744.996

Co. Ltd. (DAWAA) Saudi Obat-obatan/ Pharmacy and March 5, 2018 Medicine Distribution

PT Phapros Tbk (PEHA) Semarang Pabrik Obat-Obatan/ Tahun 1957 / 56,77% 56,77% 1.957.220.521 2.096.719.183

Drug Plant 1957

Pemilikan Tidak Langsung melalui KFA/

Indirect Ownership through KFA

PT Kimia Farma Diagnostika (KFD) Jakarta Lab Klinik/ Clinical Lab 1 Januari 2020/ 99,99% 99,99% 555.687.554 344.550.063

Pemilikan Tidak Langsung melalui PEHA/

Indirect Ownership through PEHA

PT Lucas Djaja (LD) Bandung Industri Farmasi/ Tahun 1968/ 90,22% 90,22% 315.175.404 312.984.578 Pharmaceutical Industry 1968

PT Marin Liza Bandung Industri Farmasi/ Tahun 1973/ 99,91% 99,91% 77.632.747 70.873.152 Pharmaceutical Industry 1973

Persentase Kepemilikan/

% of Ownership Total Assets Before Elimination Total Aset Sebelum Eliminasi/

Dalam laporan keuangan konsolidasian interim ini, Perusahaan dan entitas anak secara bersama-sama disebut sebagai

“Grup”.

In these consolidated interim financial statements, the Company and its subsidiaries are collectively referred as

“the Group”.

1. e. Penawaran Umum Saham Perdana 1. e. Initial Public Offering Jumlah saham Perusahaan sebelum

penawaran umum perdana adalah sejumlah 3.000.000.000 lembar, terdiri dari 2.999.999.999 saham seri B dan 1 saham seri A Dwiwarna yang seluruhnya dimiliki oleh Pemerintah Republik Indonesia.

The total number of the Company’s shares before initial public offering was 3,000,000,000 shares, consist of 2,999,999,999 series B shares and 1 series A Dwiwarna share, which were held by the Government of the Republic of Indonesia.

(17)

1. UMUM (Lanjutan) 1. GENERAL (Continued) 1. e. Penawaran Umum Saham Perdana

(Lanjutan)

1. e. Initial Public Offering (Continued)

Pada tanggal 14 Juni 2001, Perusahaan memperoleh pernyataan efektif dari Ketua Badan Pengawas Pasar Modal (BAPEPAM) dengan suratnya No S-1415/PM/2001 untuk melakukan penawaran umum atas 500.000.000 saham seri B kepada masyarakat dan 54.000.000 saham seri B kepada karyawan dan manajemen. Pada tanggal 4 Juli 2001, seluruh saham tersebut telah dicatatkan pada Bursa Efek Indonesia.

On June 14, 2001, the Company obtained the notice of effectiveness from the Chairman of the Capital Market Supervisory Board (BAPEPAM) in its letter No S-1415/PM/2001 for its public offering of 500,000,000 series B shares to the public and 54,000,000 series B shares to employees and management stock option. On July 4, 2001, all shares were listed at the Indonesia Stock Exchange.

2. IKHTISAR KEBIJAKAN AKUNTANSI

SIGNIFIKAN 2. SUMMARY OF SIGNIFICANT ACCOUNTING

POLICIES 2. a. Kepatuhan Terhadap Standar

Akuntansi Keuangan (“SAK”) 2. a. Compliance to the Financial Accounting Standards (“SAK”)

Laporan keuangan konsolidasian interim telah disusun dan disajikan sesuai dengan Standar Akuntansi Keuangan di Indonesia yang meliputi Pernyataan Standar Akuntansi Keuangan (“PSAK”) dan Interpretasi Standar Akuntansi Keuangan (“ISAK”) yang diterbitkan oleh Dewan Standar Akuntansi Keuangan – Ikatan Akuntan Indonesia (“DSAK–IAI”), serta peraturan Pasar Modal yang berlaku antara lain Peraturan Otoritas Jasa Keuangan/ Badan Pengawas Pasar Modal dan Lembaga Keuangan (OJK/Bapepam- LK) No. VIII.G.7 tentang pedoman penyajian laporan keuangan, keputusan Ketua Bapepam-LK No.KEP-347/BL/2012 tentang penyajian dan pengungkapan laporan keuangan emiten atau perusahaan publik.

The consolidated interim financial statements were prepared and presented in accordance with Indonesian Financial Accounting Standards which include the Statements of Financial Accounting Standards ("PSAK”) and Interpretation of Financial Accounting Standards (“ISAK”) issued by the Financial Accounting Standard Board – Indonesian Institute of Accountant (“DSAK–IAI”), and regulations in the Capital Market include Regulations, others, of Financial Sevices Authority/

Capital Market and Supervisory Board and Financial Institution (OJK/Bapepam-LK) No. VIII.G.7 regarding guidelines for the presentation of financial statements, decree of Chairman of Bapepam-LK No.

KEP-347/BL/2012 regarding presentation and disclosure of financial statements of the issuer or public company.

(18)

Statements

Laporan keuangan konsolidasian disusun dan disajikan berdasarkan asumsi kelangsungan usaha serta atas dasar akrual, kecuali laporan arus kas konsolidasian. Dasar pengukuran dalam penyusunan laporan keuangan konsolidasian ini adalah konsep biaya perolehan, kecuali beberapa akun tertentu yang didasarkan pengukuran lain sebagaimana dijelaskan dalam kebijakan akuntansi masing-masing akun tersebut.

Biaya perolehan umumnya didasarkan pada nilai wajar imbalan yang diserahkan dalam pemerolehan aset.

The consolidated statements have been prepared and presented based on going concern assumption and accrual basis of accounting, except for these consolidated statements of cash flows. Basis of measurement in preparation of these consolidated financial statements is the historical costs concept, except for certain accounts which have been prepared on the basis of other measurements as described in their respective policies. Historical cost is generally based on the fair value of the consideration given in exchange for assets.

Laporan arus kas konsolidasian disajikan

dengan metode langsung (direct method) dengan mengelompokkan arus kas dalam aktivitas operasi, investasi dan pendanaan.

The consolidated statements of cash flows are prepared using the direct method by classifying cash flows into operating, investing and financing activities.

Mata uang penyajian yang digunakan

dalam penyusunan laporan keuangan konsolidasian ini adalah Rupiah yang merupakan mata uang fungsional Grup.

Setiap entitas di dalam Grup menetapkan mata uang fungsional sendiri dan unsur- unsur dalam laporan keuangan dari setiap entitas diukur berdasarkan mata uang fungsional tersebut. (Catatan 2.g).

The presentation currency used in the preparation of the consolidated financial statements is Indonesian Rupiah, which is the Group’s functional currency. Each entity in the Group determines its own functional currency and items included in the financial statements of each entity are measured using that functional currency (Note 2.g).

(19)

2. IKHTISAR KEBIJAKAN AKUNTANSI

SIGNIFIKAN (Lanjutan) 2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued)

2. c. Perubahan pada pernyataan standar akuntansi keuangan dan interpretasi pernyataan standar akuntansi keuangan

2. c. Changes to the statements of financial accounting standards and interpretations of statement of financial accounting standards

Standar baru, amandemen dan interpretasi yang telah diterbitkan, namun belum berlaku efektif untuk tahun buku yang dimulai pada atau setelah 1 Januari 2021 adalah sebagai berikut:

New standards, amendments and interpretations issued but only effective for financial years beginning on or after January 1, 2021 are as follows:

- Amandemen PSAK No. 22,

“Kombinasi Bisnis tentang Definisi Bisnis”;

- Amendment to PSAK No. 22,

“Business Combination – Definition of a Business”;

“Kombinasi Bisnis tentang Referensi ke Kerangka Konseptual”;

“Business Combination – Reference to the Conceptual Framework”;

- Amandemen PSAK No. 57, “Provisi, Liabilitas Kontinjensi dan Aset Kontinjensi tentang Kontrak Memberatkan - Biaya Memenuhi Kontrak”;

“Provision, Contingent Liabilities and Contingent Assets - Onerous Contracts, Cost of Fulfilling the Contracts”;

“Instrumen Keuangan”; Amandemen PSAK No. 55, “Instrumen Keuangan:

Pengakuan dan Pengukuran”;

Amandemen PSAK No. 60,

“Instrumen Keuangan:

Pengungkapan”; Amandemen PSAK No. 62, “Kontrak Asuransi”; dan Amandemen PSAK No. 73, “Sewa”

tentang “Reformasi Acuan Suku Bunga - Tahap 2”; dan

“Financial Instruments”; Amendment to PSAK No. 55, “Financial Instruments: Recognition and Measurement”; Amendment to PSAK No. 60, “Financial Instruments:

Disclosures”; Amendment to PSAK No. 62, “Insurance Contracts”; and Amendment to PSAK No. 73,

“Leases” - “Interest Rate Benchmark Reform - Phase 2”; and

- Amandemen PSAK No. 73, “Sewa tentang Konsesi Sewa terkait Covid- 19 setelah 30 Juni 2021”.

- Amendment to PSAK No. 73, “Leases regarding Lease Concessions Related to Covid-19 after June 30, 2021”.

(20)

Laporan keuangan konsolidasian meliputi laporan keuangan Perusahaan dan Entitas Anaknya seperti disebutkan pada Catatan 1d.

The consolidated financial statements comprise the financial statements of the Company and its Subsidiaries as described in Note 1d.

Pengendalian diperoleh ketika Perusahaan terekspos, atau memiliki hak atas imbal hasil variabel dari keterlibatannya dengan investee dan memiliki kemampuan untuk mempengaruhi imbal hasil tersebut melalui kekuasaannya atas investee. Secara khusus, Perusahaan mengendalikan investee jika, dan hanya jika, Perusahaan memiliki seluruh hal berikut ini:

Control is achieved when the Company is exposed, or has rights, to variable returns from its involvement with the investee and has the ability to affect those returns through its power over the investee.

Specifically, the Company controls an investee if, and only if, the Company has all of the following:

a. Kekuasaan atas investee (misalnya adanya hak yang memberikan Perusahaan kemampuan saat ini untuk mengarahkan aktivitas investee yang relevan);

a. Power over the investee (i.e., existing rights that give investor the current ability to direct the relevant activities of the investee);

b. Exposur atau hak atas imbal hasil variabel dari keterlibatan Perusahaan dengan investee; dan

b. Exposure, or right, to variable returns from investor’s involvement with the investee; and

c. Kemampuan untuk menggunakan kekuasaannya atas investee untuk mempengaruhi imbal hasil Perusahaan.

c. The ability to use its power over the investee to affect the investor’s returns.

Umumnya, kepemilikan hak suara mayoritas (a majority of voting rights) menghasilkan pengendalian.

Generally, there is a presumption that a majority of voting rights result in control.